Neurocrine CLO vests 4,483 shares in PRSU award

NBIX’s chief legal officer had PRSUs vest into shares, with a portion withheld to cover tax obligations and no open-market sales reported.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Legal Officer Darin Lippoldt received 4,483 shares of common stock on September 11, 2026 through the vesting of previously granted performance restricted stock units (PRSUs) after achievement of a specified performance metric was certified.

On the same date, 2,419 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements related to the PRSU vesting, and the disclosure states that no shares were sold. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lippoldt Darin

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	4,483	$0.00	$0.00
Tax Withholding	Common Stock F2	2,419	$156.22	$378K

Holdings After Transaction: Common Stock — 56,793 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Key Figures

Shares acquired from PRSU vesting: 4,483 shares Shares withheld for tax withholding: 2,419 shares Withholding reference price: $156.22 per share +2 more

5 metrics

Shares acquired from PRSU vesting 4,483 shares Common stock delivered on September 11, 2026 upon certification of a performance metric

Shares withheld for tax withholding 2,419 shares Withheld by the company on September 11, 2026 for PRSU-related tax obligations

Withholding reference price $156.22 per share Price applied to the 2,419 shares withheld to satisfy tax withholding requirements

Net buy/sell direction Neutral (no net buy or sale shares reported) Transaction summary across reported non-derivative transactions

Tax-related disposition shares 2,419 shares Reported as payment of tax liability by delivering or withholding securities

Key Terms

performance restricted stock units (PRSUs), tax withholding requirements, vest, performance metrics

4 terms

performance restricted stock units (PRSUs) financial

"was previously granted performance restricted stock units (PRSUs) that vest"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

vest financial

"PRSUs that vest upon the achievement of certain performance metrics"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

performance metrics financial

"PRSUs that vest upon the achievement of certain performance metrics"

Performance metrics are concrete numbers or ratios that show how well a business, product, or investment is doing—like speed, fuel use and mileage on a car’s dashboard. They measure things investors care about, such as sales growth, profitability, cash flow, customer retention or efficiency, so readers can compare progress, spot strengths or problems, and make informed decisions about buying, holding or selling shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award activity did NBIX report for Chief Legal Officer Darin Lippoldt?

NBIX reported that Chief Legal Officer Darin Lippoldt had 4,483 shares of common stock delivered on September 11, 2026 from vesting of previously granted PRSUs after a performance metric was certified as achieved.

How many NBIX shares were withheld for taxes in this Form 4?

The company withheld 2,419 shares of NBIX common stock at $156.22 per share to satisfy tax withholding requirements related to the vesting of performance restricted stock units.

Did the NBIX Form 4 report any open-market sale or purchase by the insider?

No. The filing states that the 2,419 shares were withheld by Neurocrine Biosciences to cover tax withholding on PRSU vesting and explicitly notes that no shares were sold in the market.

Were the NBIX PRSUs tied to performance conditions?

Yes. The insider had previously been granted performance restricted stock units (PRSUs) that vest upon achievement of certain performance metrics, and achievement of one such metric was certified on September 11, 2026.

Was a Rule 10b5-1 trading plan involved in this NBIX Form 4?

No. The Form 4 indicates that no Rule 10b5-1 trading plan was affirmed for these transactions; they reflect PRSU vesting and associated tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:07 PM Accepted by SEC EDGAR 09/15/2026 - 05:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippoldt Darin

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		4,483	A	$0	59,212	D
Common Stock	09/11/2026		F(2)		2,419	D	$156.22	56,793	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Remarks:

	/s/ Darin Lippoldt	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)